GlassScriptPhysician profile
Kimberly J Norris
NPI 1659335305
$3,239.15
in general payments reported to CMS, 2019-2025
26 companies · $979 in 2025
The $979 reported for 2025 was more than what 77% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $272 · 2020: $142 · 2021: $341 · 2022: $259 · 2023: $413 · 2024: $832 · 2025: $979.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,155 · Entertainment: $69.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,155.42 |
| Entertainment | $69.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $519.95 | 2024-2025 | Tepezza |
| Alcon Vision LLC | $348.26 | 2020-2025 | Hydrus Microstent, Total30, Eysuvis |
| Sun Pharmaceutical Industries INC. | $268.45 | 2019-2025 | Cequa |
| Abbvie INC. | $225.55 | 2022-2024 | |
| Tarsus Pharmaceuticals, INC. | $200.03 | 2024-2025 | Xdemvy |
| Kala Pharmaceuticals, INC. | $190.77 | 2020-2021 | |
| Medline Industries LP | $182.97 | 2025 | |
| Hoffmann-La Roche Limited | $147.67 | 2019 | |
| Bausch & Lomb Americas INC. | $137.68 | 2022-2025 | Xiidra, Miebo |
| Novartis Pharmaceuticals Corporation | $123.93 | 2019-2022 | |
| Johnson & Johnson Vision Care, INC. | $115.88 | 2021-2024 | Acuvue |
| Oyster Point Pharma, INC. | $107.06 | 2023-2025 | Tyrvaya, Ryzumvi |
| Horizon Therapeutics Plc | $103.44 | 2022-2023 | Tepezza |
| Dompe US, INC. | $102.40 | 2022-2025 | Oxervate |
| Biotissue Holdings INC. | $99.69 | 2019-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $83.41 | 2019-2022 | |
| Optos, INC. | $69.15 | 2023 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Merck Sharp & Dohme LLC | $42.25 | 2024-2025 | Bridion |
| Aerie Pharmaceuticals, INC. | $36.98 | 2020-2021 | |
| Harrow Eye, LLC | $28.76 | 2025 | Vevye |
| Astellas Pharma US INC | $24.19 | 2024 | Izervay |
| Coopervision INC. | $23.41 | 2020 | |
| Rxsight INC | $17.35 | 2024 | Rxsight Injector Cartridge, Light Adjustable Lens (Lal), Rxsight Contact Lens |
| Mallinckrodt Hospital Products INC. | $16.72 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $11.94 | 2019 | |
| Shire North American Group INC | $11.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Norris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.